RxDoctor Payments DataLook up a doctor →

Madaiah Revana, MD

Interventional Cardiology · Humble, TXNPI 1013997360

Payments from drug & device makers

$253,534in general payments, 2019–2025

Across 908 payments — averaging $279.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$161K
  • Johnson & Johnson$54K
  • Amarin Pharma, Inc.$8K
  • Medtronic$7K
  • Abbott$6K
  • Biotronik Inc.$3K
  • plus $15K from 45 others

What the payments were for

  • Consulting fees$6501%
  • Speaking & faculty fees$55,09560%
  • Travel & lodging$4,2615%
  • Food & beverage$32,12935%
  • Education$2240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$253,534 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$506,001
Medicare patients
257
Services billed
3,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban337$382,860
VyndamaxTafamidis14$308,616
EntrestoSacubitril/Valsartan191$258,435
EliquisApixaban112$134,489
BrilintaTicagrelor86$77,043
OzempicSemaglutide45$63,806
FarxigaDapagliflozin Propanediol48$58,134
MounjaroTirzepatide40$50,002
VascepaIcosapent Ethyl50$42,805
NexlizetBempedoic Acid/Ezetimibe56$41,242
JardianceEmpagliflozin31$36,413
MultaqDronedarone Hcl21$36,312
Repatha SyringeEvolocumab18$26,212
Ranolazine ErRanolazine154$24,425
JanuviaSitagliptin Phosphate14$18,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$129$443,105126 claims
Johnson & JohnsonXarelto$53,561$382,860337 claims
NovartisEntresto$909$258,435191 claims
AstraZenecaBrilinta, Farxiga$286$135,177134 claims
Novo NordiskOzempic$342$63,80645 claims
Esperion Therapeutics, Inc.Nexlizet$593$41,24256 claims
Boehringer IngelheimJardiance$458$36,41331 claims
Sanofi-aventis U.S. LLCMultaq$433$36,31221 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$57$24,15148 claims
MerckJanuvia$509$18,64814 claims
Lexicon Pharmaceuticals, Inc.Inpefa$385$13,79814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →